Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS): A Randomized, Two-Arm, Parallel, Double-Blind, Multi-Centre, Placebo Controlled Study
Sponsor: Calliditas Therapeutics AB
Listed as NCT00160082, this NA trial focuses on Post Polio Syndrome, PPS and remains completed. Sponsored by Calliditas Therapeutics AB, it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Mar 2018 — Jun 2018 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Mar 2018 [monthly]
Completed NA
First recorded
Jan 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Calliditas Therapeutics AB
For direct contact, visit the study record on ClinicalTrials.gov .